Satu Mustjoki

Person

Latest publications

  1. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

    EURO-SKI Investigators Jun 2018 In : Lancet Oncology. 19, 6, p. 747-757 11 p.

    Research output: Contribution to journalArticleScientificpeer-review

  2. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients

    He, L., Tang, J., Andersson, E. I., Timonen, S., Koschmieder, S., Wennerberg, K., Mustjoki, S. & Aittokallio, T. 1 May 2018 In : Cancer Research. 78, 9, p. 2407-2418 12 p.

    Research output: Contribution to journalArticleScientificpeer-review

  3. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target

    Dufva, O. , Kankainen, M. , Kelkka, T. , Sekiguchi, N. , Awad, S. A. , Eldfors, S. , Yadav, B. , Kuusanmäki, H. , Malani, D. , Andersson, E. I. , Pietarinen, P. , Saikko, L. , Kovanen, P. E. , Ojala, T. , Lee, D. A. , Loughran, T. P. , Nakazawa, H. , Suzumiya, J. , Suzuki, R. , Ko, Y. H. & 7 others Kim, W. S., Chuang, S-S., Aittokallio, T., Chan, W. C., Ohshima, K., Ishida, F. & Mustjoki, S. 19 Apr 2018 In : Nature Communications. 9, 12 p., 1567

    Research output: Contribution to journalArticleScientificpeer-review

View all (151) »

Education

Lääketieteen tohtori

ID: 119665